ABN AMRO Bank N.V. Has $75.56 Million Holdings in Zoetis Inc. $ZTS

ABN AMRO Bank N.V. lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 63.3% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 522,231 shares of the company’s stock after purchasing an additional 202,516 shares during the quarter. ABN AMRO Bank N.V. owned 0.12% of Zoetis worth $75,559,000 as of its most recent SEC filing.

Several other institutional investors have also made changes to their positions in the stock. Halbert Hargrove Global Advisors LLC lifted its position in shares of Zoetis by 496.6% during the 3rd quarter. Halbert Hargrove Global Advisors LLC now owns 173 shares of the company’s stock valued at $25,000 after acquiring an additional 144 shares during the period. REAP Financial Group LLC increased its position in shares of Zoetis by 201.5% in the second quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after purchasing an additional 131 shares during the period. NewSquare Capital LLC raised its stake in Zoetis by 69.1% in the second quarter. NewSquare Capital LLC now owns 208 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. Financial Consulate Inc. acquired a new position in Zoetis in the third quarter valued at about $39,000. Finally, SJS Investment Consulting Inc. lifted its position in Zoetis by 1,606.3% during the third quarter. SJS Investment Consulting Inc. now owns 273 shares of the company’s stock worth $40,000 after purchasing an additional 257 shares during the period. 92.80% of the stock is currently owned by institutional investors.

Zoetis Price Performance

Shares of NYSE:ZTS opened at $126.69 on Thursday. Zoetis Inc. has a one year low of $115.25 and a one year high of $177.40. The company has a debt-to-equity ratio of 1.31, a current ratio of 3.64 and a quick ratio of 2.28. The company has a market cap of $55.83 billion, a price-to-earnings ratio of 21.33, a PEG ratio of 2.11 and a beta of 0.96. The firm has a 50 day simple moving average of $124.00 and a 200 day simple moving average of $136.62.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, topping analysts’ consensus estimates of $1.62 by $0.08. The firm had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 28.21% and a return on equity of 57.19%. The company’s revenue was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.58 earnings per share. Research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 3rd. Investors of record on Tuesday, January 20th will be given a dividend of $0.53 per share. The ex-dividend date is Tuesday, January 20th. This represents a $2.12 dividend on an annualized basis and a yield of 1.7%. This is an increase from Zoetis’s previous quarterly dividend of $0.50. Zoetis’s dividend payout ratio is presently 35.69%.

Analysts Set New Price Targets

Several research firms have commented on ZTS. UBS Group set a $136.00 target price on shares of Zoetis in a report on Thursday, January 29th. Bank of America lowered shares of Zoetis from a “buy” rating to a “neutral” rating and set a $135.00 price target on the stock. in a research report on Monday, December 15th. The Goldman Sachs Group upgraded shares of Zoetis to a “buy” rating in a research report on Monday, December 15th. Stifel Nicolaus cut their target price on Zoetis from $140.00 to $130.00 and set a “hold” rating for the company in a research note on Tuesday, November 18th. Finally, Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Five investment analysts have rated the stock with a Buy rating, seven have issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $152.45.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.